Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.
A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.
David B. Weiner, of the Wistar Institute, and his laboratory, created a new therapeutic design for glioblastoma, the deadliest form of brain cancer.Â
A team at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute completed its first gene therapy for a patient with hemophilia B, the first at an adult medical center in Ohio.
RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer
The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.
A new nationwide survey of more than 750 radiation oncologists confirms that prior authorization harms people with cancer by causing treatment delays, abandoned treatments, hospitalizations and patient deaths.Â
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
A cancer therapy that prompts the body’s immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the heart’s largest blood vessels, a new study suggests.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma. Their study was published this month in the journal Blood Neoplasia.
